| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 302 | 2024 | 16196 | 6.690 |
Why?
|
| Receptor, ErbB-2 | 69 | 2024 | 2648 | 3.250 |
Why?
|
| Carcinoma, Lobular | 27 | 2022 | 617 | 2.650 |
Why?
|
| Carcinoma, Ductal, Breast | 46 | 2020 | 1233 | 2.510 |
Why?
|
| Carcinoma | 29 | 2024 | 2627 | 1.910 |
Why?
|
| Immunohistochemistry | 76 | 2024 | 7815 | 1.850 |
Why?
|
| Receptors, Estrogen | 54 | 2024 | 2264 | 1.700 |
Why?
|
| Lymphatic Metastasis | 56 | 2022 | 4967 | 1.630 |
Why?
|
| Triple Negative Breast Neoplasms | 20 | 2024 | 1372 | 1.630 |
Why?
|
| Biomarkers, Tumor | 71 | 2024 | 10701 | 1.600 |
Why?
|
| Breast | 30 | 2024 | 1379 | 1.600 |
Why?
|
| Lymph Nodes | 29 | 2022 | 3067 | 1.380 |
Why?
|
| Phyllodes Tumor | 5 | 2022 | 65 | 1.260 |
Why?
|
| Breast Neoplasms, Male | 5 | 2023 | 231 | 1.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 23 | 2015 | 693 | 1.170 |
Why?
|
| Female | 310 | 2024 | 148623 | 1.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 22 | 2022 | 1449 | 1.090 |
Why?
|
| Receptors, Progesterone | 32 | 2018 | 1646 | 0.980 |
Why?
|
| Observer Variation | 6 | 2024 | 720 | 0.980 |
Why?
|
| Neoplasm Staging | 63 | 2021 | 13979 | 0.950 |
Why?
|
| Neoadjuvant Therapy | 37 | 2024 | 5206 | 0.910 |
Why?
|
| Humans | 370 | 2024 | 271062 | 0.880 |
Why?
|
| Repressor Proteins | 14 | 2024 | 1730 | 0.830 |
Why?
|
| Mastectomy, Segmental | 17 | 2022 | 1047 | 0.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 48 | 2023 | 9084 | 0.800 |
Why?
|
| Carcinoma in Situ | 16 | 2014 | 495 | 0.780 |
Why?
|
| Fibrocystic Breast Disease | 4 | 2011 | 46 | 0.760 |
Why?
|
| Cyclin E | 6 | 2024 | 283 | 0.740 |
Why?
|
| Axilla | 18 | 2021 | 924 | 0.710 |
Why?
|
| Neoplasm Invasiveness | 37 | 2021 | 4069 | 0.700 |
Why?
|
| Middle Aged | 178 | 2024 | 90103 | 0.690 |
Why?
|
| Prognosis | 76 | 2024 | 22464 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 39 | 2023 | 10351 | 0.670 |
Why?
|
| Doxorubicin | 16 | 2011 | 3138 | 0.670 |
Why?
|
| Adult | 161 | 2024 | 81619 | 0.620 |
Why?
|
| Aged | 148 | 2024 | 73250 | 0.620 |
Why?
|
| Chemotherapy, Adjuvant | 34 | 2021 | 3972 | 0.590 |
Why?
|
| Mammography | 13 | 2019 | 1045 | 0.590 |
Why?
|
| Disease-Free Survival | 43 | 2019 | 10250 | 0.580 |
Why?
|
| GATA3 Transcription Factor | 5 | 2024 | 144 | 0.550 |
Why?
|
| Tumor Burden | 5 | 2021 | 2034 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2023 | 16603 | 0.540 |
Why?
|
| PTEN Phosphohydrolase | 11 | 2024 | 1015 | 0.540 |
Why?
|
| Langer-Giedion Syndrome | 3 | 2024 | 21 | 0.510 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 554 | 0.510 |
Why?
|
| Hair Diseases | 3 | 2024 | 42 | 0.500 |
Why?
|
| Breast Diseases | 2 | 2007 | 206 | 0.490 |
Why?
|
| Pathology Department, Hospital | 1 | 2014 | 16 | 0.490 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 3 | 2009 | 26 | 0.470 |
Why?
|
| Taxoids | 8 | 2021 | 1008 | 0.460 |
Why?
|
| Genes, erbB-2 | 6 | 2009 | 228 | 0.460 |
Why?
|
| Epithelioid Cells | 1 | 2014 | 43 | 0.460 |
Why?
|
| Pathology, Surgical | 1 | 2014 | 87 | 0.460 |
Why?
|
| Cell Line, Tumor | 44 | 2024 | 14882 | 0.450 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2005 | 744 | 0.450 |
Why?
|
| Mastectomy | 21 | 2022 | 1547 | 0.450 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2024 | 5429 | 0.450 |
Why?
|
| Biopsy, Needle | 13 | 2010 | 1401 | 0.430 |
Why?
|
| Diagnostic Errors | 3 | 2014 | 531 | 0.420 |
Why?
|
| Neoplasm, Residual | 10 | 2018 | 1740 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2019 | 2094 | 0.420 |
Why?
|
| Gene Expression Profiling | 22 | 2021 | 5165 | 0.410 |
Why?
|
| Receptors, Chemokine | 4 | 2009 | 113 | 0.410 |
Why?
|
| Aged, 80 and over | 65 | 2024 | 30966 | 0.410 |
Why?
|
| RNA, Long Noncoding | 3 | 2024 | 618 | 0.400 |
Why?
|
| Telomerase | 3 | 2004 | 533 | 0.400 |
Why?
|
| Paget's Disease, Mammary | 2 | 2023 | 40 | 0.400 |
Why?
|
| DNA, Neoplasm | 17 | 2021 | 1961 | 0.400 |
Why?
|
| ErbB Receptors | 9 | 2016 | 2379 | 0.390 |
Why?
|
| Hyperplasia | 8 | 2014 | 581 | 0.390 |
Why?
|
| Mammary Neoplasms, Animal | 4 | 2024 | 237 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 2428 | 0.380 |
Why?
|
| Precancerous Conditions | 7 | 2009 | 1066 | 0.380 |
Why?
|
| Tumor Escape | 3 | 2019 | 248 | 0.380 |
Why?
|
| Antineoplastic Agents | 18 | 2021 | 14682 | 0.370 |
Why?
|
| Neoplasm Proteins | 13 | 2021 | 3350 | 0.370 |
Why?
|
| Trastuzumab | 11 | 2024 | 736 | 0.370 |
Why?
|
| Retrospective Studies | 58 | 2023 | 39721 | 0.370 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2024 | 1708 | 0.370 |
Why?
|
| Aurora Kinase A | 5 | 2024 | 212 | 0.370 |
Why?
|
| Peptide Hydrolases | 4 | 2019 | 265 | 0.360 |
Why?
|
| Paclitaxel | 11 | 2015 | 2099 | 0.360 |
Why?
|
| Adenocarcinoma | 13 | 2016 | 7936 | 0.360 |
Why?
|
| Phosphatidylinositol 3-Kinases | 10 | 2014 | 1726 | 0.350 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2010 | 68 | 0.350 |
Why?
|
| Ki-67 Antigen | 12 | 2023 | 685 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 14 | 2021 | 4519 | 0.350 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2024 | 445 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 9 | 2015 | 1885 | 0.340 |
Why?
|
| B7-H1 Antigen | 4 | 2024 | 1070 | 0.340 |
Why?
|
| NF-kappa B | 7 | 2019 | 1584 | 0.330 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 9 | 2021 | 531 | 0.330 |
Why?
|
| Mesothelioma | 1 | 2014 | 558 | 0.320 |
Why?
|
| Referral and Consultation | 1 | 2014 | 939 | 0.320 |
Why?
|
| Radiation Oncology | 1 | 2014 | 557 | 0.320 |
Why?
|
| RNA, Messenger | 17 | 2015 | 6485 | 0.320 |
Why?
|
| Pathology, Clinical | 2 | 2022 | 154 | 0.310 |
Why?
|
| Estrogen Receptor alpha | 8 | 2016 | 746 | 0.310 |
Why?
|
| Mice | 47 | 2024 | 36039 | 0.310 |
Why?
|
| Receptors, CXCR4 | 4 | 2009 | 278 | 0.310 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2024 | 87 | 0.310 |
Why?
|
| Keratins | 11 | 2009 | 352 | 0.310 |
Why?
|
| Carcinoma, Ductal | 4 | 2006 | 144 | 0.300 |
Why?
|
| Transglutaminases | 2 | 2005 | 100 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2005 | 1547 | 0.300 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 87 | 0.300 |
Why?
|
| Up-Regulation | 16 | 2019 | 2466 | 0.290 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 5326 | 0.290 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 1011 | 0.290 |
Why?
|
| Lymph Node Excision | 9 | 2021 | 2044 | 0.290 |
Why?
|
| Cell Nucleus | 14 | 2024 | 1743 | 0.290 |
Why?
|
| DNA Copy Number Variations | 5 | 2017 | 1546 | 0.290 |
Why?
|
| DNA Repair | 3 | 2024 | 1886 | 0.290 |
Why?
|
| Sarcoma | 8 | 2022 | 1839 | 0.290 |
Why?
|
| Intraoperative Care | 2 | 2019 | 274 | 0.280 |
Why?
|
| Neoplasm Grading | 7 | 2024 | 1820 | 0.280 |
Why?
|
| Cell Proliferation | 18 | 2024 | 7307 | 0.280 |
Why?
|
| Signal Transduction | 25 | 2021 | 12221 | 0.280 |
Why?
|
| Epithelial-Mesenchymal Transition | 7 | 2022 | 1004 | 0.270 |
Why?
|
| Animals | 52 | 2024 | 62826 | 0.270 |
Why?
|
| Bone Neoplasms | 7 | 2022 | 2667 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 5 | 2012 | 704 | 0.270 |
Why?
|
| Genes, Tumor Suppressor | 10 | 2015 | 1119 | 0.270 |
Why?
|
| Gangliosides | 2 | 2021 | 114 | 0.270 |
Why?
|
| Cytoplasm | 12 | 2016 | 718 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2018 | 3653 | 0.270 |
Why?
|
| Fingers | 2 | 2024 | 129 | 0.260 |
Why?
|
| Proportional Hazards Models | 17 | 2018 | 5087 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 16 | 2013 | 1214 | 0.260 |
Why?
|
| Nuclear Proteins | 6 | 2015 | 3460 | 0.260 |
Why?
|
| Cell Division | 13 | 2008 | 2717 | 0.260 |
Why?
|
| Nose | 2 | 2024 | 137 | 0.260 |
Why?
|
| Fluorouracil | 12 | 2014 | 1987 | 0.260 |
Why?
|
| World Health Organization | 2 | 2024 | 329 | 0.250 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2024 | 499 | 0.250 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2021 | 3657 | 0.250 |
Why?
|
| Genomics | 5 | 2021 | 2818 | 0.250 |
Why?
|
| Paget Disease, Extramammary | 2 | 2023 | 54 | 0.250 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 7 | 2019 | 1293 | 0.250 |
Why?
|
| Transcription Factors | 13 | 2013 | 5497 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2004 | 235 | 0.250 |
Why?
|
| In Situ Hybridization, Fluorescence | 12 | 2023 | 2312 | 0.250 |
Why?
|
| src-Family Kinases | 5 | 2013 | 487 | 0.240 |
Why?
|
| Predictive Value of Tests | 19 | 2021 | 4982 | 0.240 |
Why?
|
| COP9 Signalosome Complex | 4 | 2019 | 80 | 0.240 |
Why?
|
| Ovarian Neoplasms | 7 | 2023 | 4774 | 0.240 |
Why?
|
| Neoplastic Stem Cells | 4 | 2021 | 1469 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 9 | 2019 | 2471 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2024 | 51 | 0.230 |
Why?
|
| GTP-Binding Proteins | 2 | 2005 | 346 | 0.230 |
Why?
|
| Adenoids | 1 | 2024 | 11 | 0.230 |
Why?
|
| Proteomics | 5 | 2023 | 1437 | 0.230 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2024 | 29 | 0.230 |
Why?
|
| Lung Neoplasms | 11 | 2021 | 11776 | 0.230 |
Why?
|
| CDC2 Protein Kinase | 1 | 2024 | 188 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2024 | 3929 | 0.230 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 208 | 0.230 |
Why?
|
| Combined Modality Therapy | 20 | 2018 | 9045 | 0.230 |
Why?
|
| Transforming Growth Factor beta | 4 | 2015 | 1133 | 0.230 |
Why?
|
| Mammary Glands, Animal | 6 | 2016 | 635 | 0.230 |
Why?
|
| Survival Analysis | 21 | 2021 | 9305 | 0.220 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 4124 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 26 | 2008 | 5834 | 0.220 |
Why?
|
| Cyclophosphamide | 14 | 2014 | 3231 | 0.220 |
Why?
|
| Multivariate Analysis | 9 | 2018 | 4332 | 0.220 |
Why?
|
| In Situ Hybridization | 9 | 2010 | 1062 | 0.220 |
Why?
|
| Mutation | 21 | 2021 | 15861 | 0.220 |
Why?
|
| RNA, Small Nucleolar | 1 | 2023 | 25 | 0.220 |
Why?
|
| Immunologic Memory | 2 | 2021 | 380 | 0.220 |
Why?
|
| Apoptosis | 11 | 2024 | 7862 | 0.220 |
Why?
|
| Anthracyclines | 4 | 2021 | 339 | 0.220 |
Why?
|
| Follow-Up Studies | 25 | 2019 | 15249 | 0.220 |
Why?
|
| Parathyroid Neoplasms | 2 | 1999 | 187 | 0.210 |
Why?
|
| Lipolysis | 1 | 2023 | 108 | 0.210 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2024 | 1842 | 0.210 |
Why?
|
| Kynurenine | 1 | 2023 | 67 | 0.210 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2350 | 0.210 |
Why?
|
| Mammaglobin A | 1 | 2022 | 14 | 0.210 |
Why?
|
| Mice, Nude | 10 | 2021 | 4361 | 0.210 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 34 | 0.200 |
Why?
|
| Treatment Outcome | 33 | 2021 | 33851 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 490 | 0.200 |
Why?
|
| Cell Movement | 9 | 2021 | 2504 | 0.200 |
Why?
|
| 14-3-3 Proteins | 2 | 2015 | 143 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 2337 | 0.200 |
Why?
|
| Down-Regulation | 11 | 2015 | 2109 | 0.200 |
Why?
|
| Oncogenes | 2 | 2019 | 700 | 0.190 |
Why?
|
| Diagnosis, Differential | 12 | 2016 | 4887 | 0.190 |
Why?
|
| Cystadenoma | 2 | 2014 | 29 | 0.190 |
Why?
|
| Gene Amplification | 6 | 2017 | 769 | 0.190 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 37 | 0.190 |
Why?
|
| Reproducibility of Results | 8 | 2024 | 6187 | 0.190 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 2993 | 0.190 |
Why?
|
| Margins of Excision | 2 | 2022 | 314 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 6251 | 0.180 |
Why?
|
| Immunoconjugates | 1 | 2024 | 315 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 154 | 0.180 |
Why?
|
| Enzyme Precursors | 4 | 2005 | 73 | 0.180 |
Why?
|
| CD4 Antigens | 1 | 2021 | 172 | 0.180 |
Why?
|
| CD8 Antigens | 1 | 2021 | 174 | 0.180 |
Why?
|
| RNA, Neoplasm | 7 | 2021 | 811 | 0.180 |
Why?
|
| Adenoma | 3 | 2019 | 741 | 0.180 |
Why?
|
| Phosphorylation | 14 | 2024 | 4993 | 0.180 |
Why?
|
| Carcinogenesis | 2 | 2019 | 1032 | 0.180 |
Why?
|
| DNA Methylation | 5 | 2015 | 2745 | 0.180 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 388 | 0.180 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2008 | 441 | 0.170 |
Why?
|
| DNA-Binding Proteins | 6 | 2015 | 5042 | 0.170 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2010 | 557 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2023 | 329 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 1656 | 0.170 |
Why?
|
| Blotting, Western | 14 | 2016 | 3651 | 0.170 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2002 | 381 | 0.170 |
Why?
|
| Chondrosarcoma | 1 | 2022 | 214 | 0.170 |
Why?
|
| Transcriptome | 2 | 2021 | 1935 | 0.170 |
Why?
|
| PHD Zinc Fingers | 1 | 2019 | 4 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2006 | 559 | 0.170 |
Why?
|
| Histone Deacetylases | 3 | 2010 | 366 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2023 | 137 | 0.160 |
Why?
|
| Protein Kinases | 3 | 2008 | 917 | 0.160 |
Why?
|
| Disease Progression | 12 | 2023 | 6898 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 142 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2021 | 640 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 4328 | 0.160 |
Why?
|
| Histone Code | 1 | 2019 | 86 | 0.160 |
Why?
|
| Trans-Activators | 7 | 2010 | 1655 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2019 | 289 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 1913 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2007 | 145 | 0.150 |
Why?
|
| DNA Adducts | 4 | 2003 | 209 | 0.150 |
Why?
|
| Neuregulin-1 | 3 | 2003 | 89 | 0.150 |
Why?
|
| Chromosome Aberrations | 4 | 2011 | 2022 | 0.150 |
Why?
|
| Epithelial Cells | 6 | 2022 | 1890 | 0.150 |
Why?
|
| Polymorphism, Genetic | 6 | 2006 | 1522 | 0.150 |
Why?
|
| Cyclin D1 | 4 | 2010 | 589 | 0.150 |
Why?
|
| Ubiquitination | 5 | 2019 | 577 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2012 | 3397 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2019 | 879 | 0.150 |
Why?
|
| Survival Rate | 16 | 2021 | 12518 | 0.140 |
Why?
|
| Oncogene Proteins | 2 | 2009 | 371 | 0.140 |
Why?
|
| Protein Isoforms | 3 | 2016 | 861 | 0.140 |
Why?
|
| Multigene Family | 2 | 2016 | 459 | 0.140 |
Why?
|
| Chromosomes, Human, Y | 2 | 2014 | 51 | 0.140 |
Why?
|
| CA-125 Antigen | 1 | 1998 | 228 | 0.140 |
Why?
|
| Microfilament Proteins | 4 | 2019 | 496 | 0.140 |
Why?
|
| Gene Silencing | 4 | 2015 | 834 | 0.140 |
Why?
|
| Cadherins | 5 | 2019 | 676 | 0.140 |
Why?
|
| Epirubicin | 4 | 2014 | 159 | 0.140 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 1998 | 178 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 1322 | 0.140 |
Why?
|
| Carrier Proteins | 6 | 2019 | 2123 | 0.140 |
Why?
|
| Skin Neoplasms | 5 | 2023 | 4838 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2023 | 4964 | 0.130 |
Why?
|
| Risk Assessment | 10 | 2019 | 6832 | 0.130 |
Why?
|
| Fibroadenoma | 1 | 2016 | 28 | 0.130 |
Why?
|
| Cytodiagnosis | 3 | 2009 | 228 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2011 | 527 | 0.130 |
Why?
|
| Epithelium | 4 | 2016 | 805 | 0.130 |
Why?
|
| Prospective Studies | 16 | 2021 | 13375 | 0.130 |
Why?
|
| Gene Expression | 8 | 2014 | 3679 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2016 | 5438 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2014 | 1571 | 0.130 |
Why?
|
| Molecular Medicine | 1 | 2015 | 5 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 189 | 0.130 |
Why?
|
| Neoplasm Transplantation | 7 | 2019 | 1567 | 0.130 |
Why?
|
| Male | 35 | 2023 | 128516 | 0.130 |
Why?
|
| Estrogen Receptor beta | 2 | 2007 | 168 | 0.130 |
Why?
|
| Mastectomy, Radical | 2 | 2005 | 40 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 1998 | 427 | 0.130 |
Why?
|
| Flow Cytometry | 13 | 2004 | 3086 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 1999 | 429 | 0.130 |
Why?
|
| Specimen Handling | 2 | 2015 | 311 | 0.120 |
Why?
|
| Integrin alpha6beta4 | 2 | 2005 | 32 | 0.120 |
Why?
|
| Transplantation, Heterologous | 4 | 2019 | 1089 | 0.120 |
Why?
|
| Homeodomain Proteins | 4 | 2014 | 1135 | 0.120 |
Why?
|
| Hyaluronan Receptors | 4 | 2013 | 250 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2015 | 75 | 0.120 |
Why?
|
| Otx Transcription Factors | 1 | 2014 | 25 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 253 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2011 | 741 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 917 | 0.120 |
Why?
|
| Chemokines, CXC | 3 | 2005 | 129 | 0.120 |
Why?
|
| R-SNARE Proteins | 1 | 2014 | 19 | 0.120 |
Why?
|
| Osteosarcoma | 1 | 2022 | 948 | 0.120 |
Why?
|
| Nomograms | 1 | 2017 | 313 | 0.120 |
Why?
|
| Gene Dosage | 2 | 2014 | 827 | 0.120 |
Why?
|
| Cell Adhesion | 5 | 2021 | 1047 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2019 | 2909 | 0.120 |
Why?
|
| Brain Neoplasms | 4 | 2015 | 4981 | 0.120 |
Why?
|
| Protein Kinase C-alpha | 1 | 2014 | 68 | 0.120 |
Why?
|
| Urogenital System | 1 | 2014 | 62 | 0.120 |
Why?
|
| Cell Shape | 1 | 2004 | 129 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1089 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2016 | 1617 | 0.120 |
Why?
|
| Elafin | 1 | 2014 | 35 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2014 | 183 | 0.110 |
Why?
|
| Lymphokines | 3 | 2002 | 318 | 0.110 |
Why?
|
| Steroid Hydroxylases | 1 | 2013 | 38 | 0.110 |
Why?
|
| Young Adult | 11 | 2018 | 22063 | 0.110 |
Why?
|
| Neoplasms | 7 | 2019 | 15861 | 0.110 |
Why?
|
| Sequence Deletion | 2 | 2014 | 909 | 0.110 |
Why?
|
| Receptors, Endothelin | 1 | 2013 | 25 | 0.110 |
Why?
|
| Receptors, Angiotensin | 1 | 2013 | 45 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2013 | 50 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 5 | 2018 | 2474 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1380 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 3145 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 7 | 2015 | 3250 | 0.110 |
Why?
|
| Biopsy | 5 | 2021 | 3544 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2400 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 745 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 280 | 0.110 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 40 | 0.110 |
Why?
|
| Glycolysis | 1 | 2016 | 534 | 0.110 |
Why?
|
| Exosomes | 1 | 2015 | 253 | 0.110 |
Why?
|
| Sirolimus | 3 | 2014 | 831 | 0.110 |
Why?
|
| Membrane Glycoproteins | 3 | 2014 | 1107 | 0.100 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2012 | 108 | 0.100 |
Why?
|
| Clinical Trials as Topic | 6 | 2009 | 3861 | 0.100 |
Why?
|
| Regression Analysis | 5 | 2014 | 1567 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 303 | 0.100 |
Why?
|
| Quinazolines | 2 | 2016 | 953 | 0.100 |
Why?
|
| Ultrasonography, Mammary | 4 | 2006 | 386 | 0.100 |
Why?
|
| Cell Cycle Proteins | 4 | 2008 | 2125 | 0.100 |
Why?
|
| Age Factors | 5 | 2011 | 5487 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 1146 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2003 | 179 | 0.100 |
Why?
|
| Urogenital Abnormalities | 1 | 2014 | 175 | 0.100 |
Why?
|
| Receptors, CCR7 | 3 | 2009 | 38 | 0.100 |
Why?
|
| Radiotherapy | 3 | 2015 | 1858 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2010 | 354 | 0.100 |
Why?
|
| Estrogens | 2 | 2014 | 845 | 0.100 |
Why?
|
| Tamoxifen | 7 | 2005 | 907 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2014 | 2266 | 0.100 |
Why?
|
| Magnetic Phenomena | 2 | 2022 | 28 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2014 | 323 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1514 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1821 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1335 | 0.100 |
Why?
|
| Ear, Middle | 1 | 1991 | 52 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2009 | 2489 | 0.090 |
Why?
|
| Time Factors | 13 | 2014 | 13112 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2004 | 686 | 0.090 |
Why?
|
| Biomarkers | 5 | 2019 | 5107 | 0.090 |
Why?
|
| Mice, Transgenic | 7 | 2016 | 4373 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 428 | 0.090 |
Why?
|
| Paneth Cells | 1 | 2010 | 27 | 0.090 |
Why?
|
| Ear Neoplasms | 1 | 1991 | 62 | 0.090 |
Why?
|
| Pseudogenes | 1 | 2011 | 91 | 0.090 |
Why?
|
| Sensitivity and Specificity | 9 | 2024 | 5187 | 0.090 |
Why?
|
| Desmin | 4 | 1998 | 64 | 0.090 |
Why?
|
| Molecular Weight | 2 | 2024 | 728 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2017 | 1462 | 0.090 |
Why?
|
| Interleukins | 2 | 2004 | 341 | 0.090 |
Why?
|
| Wnt1 Protein | 1 | 2010 | 102 | 0.090 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2024 | 162 | 0.090 |
Why?
|
| Cytoplasmic Granules | 1 | 2010 | 87 | 0.090 |
Why?
|
| Proteome | 1 | 2014 | 572 | 0.090 |
Why?
|
| Plasmacytoma | 1 | 1991 | 123 | 0.090 |
Why?
|
| Cohort Studies | 10 | 2014 | 9438 | 0.090 |
Why?
|
| Temporal Bone | 1 | 1991 | 109 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2010 | 135 | 0.090 |
Why?
|
| Pathologists | 2 | 2024 | 101 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2011 | 770 | 0.090 |
Why?
|
| Dermoid Cyst | 1 | 1990 | 39 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 87 | 0.090 |
Why?
|
| Hyalin | 1 | 1989 | 18 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2005 | 853 | 0.090 |
Why?
|
| Intestinal Mucosa | 2 | 1994 | 1124 | 0.090 |
Why?
|
| Inflammation | 5 | 2013 | 2525 | 0.090 |
Why?
|
| Bridged-Ring Compounds | 1 | 2010 | 180 | 0.090 |
Why?
|
| Microscopy, Electron | 6 | 1997 | 735 | 0.080 |
Why?
|
| Developmental Disabilities | 1 | 2014 | 687 | 0.080 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 3934 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 474 | 0.080 |
Why?
|
| Databases, Genetic | 3 | 2020 | 738 | 0.080 |
Why?
|
| Calcinosis | 2 | 2003 | 432 | 0.080 |
Why?
|
| Peptic Ulcer | 1 | 1990 | 161 | 0.080 |
Why?
|
| Leiomyoma | 1 | 1990 | 161 | 0.080 |
Why?
|
| Decision Making | 2 | 2017 | 1242 | 0.080 |
Why?
|
| Inclusion Bodies | 1 | 1989 | 91 | 0.080 |
Why?
|
| Cyclin B | 1 | 2009 | 69 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 2084 | 0.080 |
Why?
|
| Menstruation | 1 | 1989 | 37 | 0.080 |
Why?
|
| CpG Islands | 3 | 2007 | 653 | 0.080 |
Why?
|
| MCF-7 Cells | 3 | 2016 | 554 | 0.080 |
Why?
|
| Annexin A1 | 1 | 2008 | 41 | 0.080 |
Why?
|
| Drug Monitoring | 2 | 2019 | 356 | 0.080 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2008 | 31 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 496 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 1990 | 252 | 0.080 |
Why?
|
| Enzyme Activation | 6 | 2011 | 1835 | 0.080 |
Why?
|
| Myometrium | 1 | 1989 | 83 | 0.080 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 922 | 0.080 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 388 | 0.080 |
Why?
|
| Extracellular Matrix | 3 | 2006 | 533 | 0.080 |
Why?
|
| Prostatic Neoplasms | 4 | 2013 | 5992 | 0.080 |
Why?
|
| Nuclear Localization Signals | 2 | 2009 | 47 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 322 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2009 | 235 | 0.080 |
Why?
|
| Molecular Sequence Data | 10 | 2009 | 6784 | 0.080 |
Why?
|
| Melanoma | 2 | 2022 | 5529 | 0.080 |
Why?
|
| Mice, SCID | 3 | 2021 | 1855 | 0.070 |
Why?
|
| Cytokines | 5 | 2004 | 2837 | 0.070 |
Why?
|
| Infertility, Male | 1 | 2011 | 310 | 0.070 |
Why?
|
| Risk | 4 | 2018 | 1913 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 1994 | 3662 | 0.070 |
Why?
|
| Transcriptional Activation | 4 | 2005 | 1147 | 0.070 |
Why?
|
| Mesoderm | 1 | 2009 | 397 | 0.070 |
Why?
|
| Azacitidine | 2 | 2005 | 1219 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 6 | 2008 | 1502 | 0.070 |
Why?
|
| Obesity | 2 | 2023 | 2940 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 128 | 0.070 |
Why?
|
| Transfection | 6 | 2010 | 3169 | 0.070 |
Why?
|
| Amino Acid Sequence | 8 | 2009 | 4641 | 0.070 |
Why?
|
| Lymphocyte Activation | 4 | 2016 | 1733 | 0.070 |
Why?
|
| Glutathione Transferase | 3 | 2004 | 368 | 0.070 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 759 | 0.070 |
Why?
|
| Staining and Labeling | 5 | 1991 | 465 | 0.070 |
Why?
|
| Growth Inhibitors | 2 | 1998 | 164 | 0.070 |
Why?
|
| RNA Splicing | 2 | 2024 | 358 | 0.070 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 658 | 0.070 |
Why?
|
| Killer Cells, Natural | 2 | 2023 | 958 | 0.070 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 1997 | 122 | 0.070 |
Why?
|
| Genes, p53 | 2 | 2017 | 1133 | 0.070 |
Why?
|
| Paraffin Embedding | 3 | 2015 | 226 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1989 | 289 | 0.070 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 250 | 0.070 |
Why?
|
| Collagen | 2 | 2004 | 737 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 3 | 2008 | 1600 | 0.070 |
Why?
|
| Proteins | 3 | 2004 | 2047 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 624 | 0.070 |
Why?
|
| Endothelium | 1 | 2006 | 165 | 0.070 |
Why?
|
| Risk Factors | 14 | 2013 | 17829 | 0.070 |
Why?
|
| Chromosome Fragile Sites | 1 | 2005 | 38 | 0.070 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 4795 | 0.070 |
Why?
|
| Benzo(a)pyrene | 2 | 2002 | 38 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 4 | 2010 | 181 | 0.070 |
Why?
|
| Phosphoproteins | 3 | 2008 | 1229 | 0.060 |
Why?
|
| Ploidies | 5 | 1994 | 257 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 278 | 0.060 |
Why?
|
| Analysis of Variance | 5 | 2010 | 2318 | 0.060 |
Why?
|
| Protein Stability | 2 | 2016 | 375 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2003 | 451 | 0.060 |
Why?
|
| Interleukin-15 | 2 | 2023 | 189 | 0.060 |
Why?
|
| Wilms Tumor | 1 | 1988 | 297 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2004 | 754 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5237 | 0.060 |
Why?
|
| Endometrium | 1 | 1989 | 469 | 0.060 |
Why?
|
| Stereotaxic Techniques | 2 | 2003 | 183 | 0.060 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 651 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 380 | 0.060 |
Why?
|
| Cyclins | 2 | 2023 | 470 | 0.060 |
Why?
|
| Receptors, sigma | 1 | 2004 | 6 | 0.060 |
Why?
|
| Leukocyte Common Antigens | 2 | 2021 | 192 | 0.060 |
Why?
|
| Carcinoma, Papillary | 2 | 2004 | 581 | 0.060 |
Why?
|
| Cell Survival | 3 | 2009 | 3085 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 409 | 0.060 |
Why?
|
| Interleukin-6 | 3 | 2004 | 1076 | 0.060 |
Why?
|
| Vimentin | 3 | 1998 | 265 | 0.060 |
Why?
|
| Receptor, trkC | 1 | 2024 | 22 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 911 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 3539 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 1993 | 2437 | 0.060 |
Why?
|
| Spindle Apparatus | 2 | 2005 | 112 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2005 | 532 | 0.060 |
Why?
|
| Interleukin-10 | 2 | 2004 | 481 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 2 | 2002 | 104 | 0.060 |
Why?
|
| Glycoproteins | 2 | 2013 | 796 | 0.060 |
Why?
|
| Laminin | 1 | 2004 | 212 | 0.060 |
Why?
|
| Mammary Glands, Human | 3 | 2013 | 185 | 0.060 |
Why?
|
| Protein Binding | 6 | 2010 | 3536 | 0.060 |
Why?
|
| RNA Probes | 1 | 2004 | 50 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2009 | 5568 | 0.060 |
Why?
|
| DNA, Complementary | 5 | 2005 | 956 | 0.060 |
Why?
|
| Choriocarcinoma | 1 | 2004 | 49 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 303 | 0.060 |
Why?
|
| Evolution, Molecular | 2 | 2021 | 865 | 0.060 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2024 | 81 | 0.060 |
Why?
|
| Pyridines | 2 | 2019 | 1312 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2005 | 168 | 0.060 |
Why?
|
| Growth Substances | 2 | 2002 | 330 | 0.060 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 410 | 0.060 |
Why?
|
| Case-Control Studies | 7 | 2014 | 6034 | 0.060 |
Why?
|
| Papilloma | 1 | 2004 | 88 | 0.060 |
Why?
|
| Syk Kinase | 4 | 2005 | 65 | 0.060 |
Why?
|
| Actins | 5 | 2000 | 616 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2004 | 278 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2004 | 160 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2004 | 62 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1991 | 1011 | 0.060 |
Why?
|
| Pyroptosis | 1 | 2024 | 29 | 0.060 |
Why?
|
| Microtubules | 1 | 2005 | 330 | 0.060 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2005 | 128 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 2 | 2009 | 371 | 0.060 |
Why?
|
| Salivary Glands | 1 | 2024 | 141 | 0.060 |
Why?
|
| Rejuvenation | 1 | 2023 | 23 | 0.060 |
Why?
|
| Chromosome Mapping | 4 | 2007 | 1585 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 1991 | 5531 | 0.060 |
Why?
|
| Radiography | 4 | 2003 | 1988 | 0.050 |
Why?
|
| Cell Differentiation | 5 | 2022 | 4190 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 486 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 265 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 773 | 0.050 |
Why?
|
| Blotting, Northern | 4 | 2007 | 736 | 0.050 |
Why?
|
| Pregnancy | 5 | 2016 | 8096 | 0.050 |
Why?
|
| Caspases | 2 | 2002 | 699 | 0.050 |
Why?
|
| SOXF Transcription Factors | 1 | 2023 | 30 | 0.050 |
Why?
|
| p21-Activated Kinases | 4 | 2005 | 131 | 0.050 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2003 | 99 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 1153 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2004 | 635 | 0.050 |
Why?
|
| Mass Screening | 1 | 2011 | 1553 | 0.050 |
Why?
|
| Chromosome Deletion | 3 | 2014 | 1054 | 0.050 |
Why?
|
| HeLa Cells | 4 | 2013 | 1719 | 0.050 |
Why?
|
| Cocarcinogenesis | 1 | 2002 | 55 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 916 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 674 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2010 | 835 | 0.050 |
Why?
|
| Premedication | 1 | 2002 | 133 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 686 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 212 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 2 | 2008 | 851 | 0.050 |
Why?
|
| Genotype | 5 | 2016 | 4111 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2002 | 72 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2002 | 82 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2005 | 2673 | 0.050 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2002 | 41 | 0.050 |
Why?
|
| DNA Primers | 4 | 2007 | 1508 | 0.050 |
Why?
|
| DNA Damage | 2 | 2001 | 1982 | 0.050 |
Why?
|
| Carbon-Oxygen Lyases | 1 | 2001 | 14 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 446 | 0.050 |
Why?
|
| S100 Proteins | 3 | 1993 | 190 | 0.050 |
Why?
|
| Membrane Proteins | 4 | 2024 | 2959 | 0.050 |
Why?
|
| Vinblastine | 2 | 2000 | 462 | 0.050 |
Why?
|
| Alleles | 4 | 2016 | 2507 | 0.050 |
Why?
|
| Camptothecin | 1 | 2024 | 538 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 236 | 0.050 |
Why?
|
| Tyrosine | 1 | 2003 | 510 | 0.050 |
Why?
|
| Tripartite Motif Proteins | 2 | 2013 | 51 | 0.050 |
Why?
|
| Aneuploidy | 2 | 2003 | 377 | 0.050 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2001 | 51 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2002 | 185 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 308 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2021 | 68 | 0.050 |
Why?
|
| Nuclear Matrix | 1 | 2001 | 33 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 230 | 0.050 |
Why?
|
| Cluster Analysis | 3 | 2014 | 1070 | 0.050 |
Why?
|
| SEER Program | 2 | 2016 | 1044 | 0.050 |
Why?
|
| Telomere | 1 | 2004 | 533 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 635 | 0.050 |
Why?
|
| Microtomy | 1 | 2000 | 16 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2024 | 1369 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 487 | 0.050 |
Why?
|
| CD3 Complex | 1 | 2021 | 322 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2002 | 243 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 84 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 2002 | 192 | 0.050 |
Why?
|
| Melanocytes | 1 | 2001 | 240 | 0.050 |
Why?
|
| Integrin alpha6 | 2 | 2013 | 19 | 0.050 |
Why?
|
| Bowen's Disease | 1 | 2000 | 10 | 0.040 |
Why?
|
| Chemokine CCL2 | 2 | 2015 | 203 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2021 | 139 | 0.040 |
Why?
|
| Reference Values | 4 | 2006 | 1155 | 0.040 |
Why?
|
| Everolimus | 2 | 2014 | 438 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 272 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 103 | 0.040 |
Why?
|
| Intraoperative Period | 3 | 2007 | 259 | 0.040 |
Why?
|
| Cation Transport Proteins | 1 | 2021 | 172 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2003 | 719 | 0.040 |
Why?
|
| Receptors, Cytokine | 2 | 1998 | 183 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2013 | 347 | 0.040 |
Why?
|
| Co-Repressor Proteins | 3 | 2005 | 119 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2002 | 428 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2002 | 663 | 0.040 |
Why?
|
| Cell Line | 4 | 2010 | 5437 | 0.040 |
Why?
|
| Gene Library | 3 | 2005 | 357 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 1991 | 2321 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 803 | 0.040 |
Why?
|
| Cricetinae | 1 | 2000 | 793 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 1021 | 0.040 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2000 | 113 | 0.040 |
Why?
|
| Transcription, Genetic | 4 | 2009 | 3419 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 641 | 0.040 |
Why?
|
| Registries | 2 | 2021 | 2238 | 0.040 |
Why?
|
| Graft Survival | 1 | 2002 | 1093 | 0.040 |
Why?
|
| Interleukin-4 | 2 | 2013 | 292 | 0.040 |
Why?
|
| Incidence | 4 | 2018 | 5842 | 0.040 |
Why?
|
| Centrosome | 1 | 1998 | 107 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 259 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 7470 | 0.040 |
Why?
|
| Odds Ratio | 4 | 2006 | 2287 | 0.040 |
Why?
|
| Base Sequence | 5 | 2004 | 5494 | 0.040 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2018 | 48 | 0.040 |
Why?
|
| Tretinoin | 1 | 2000 | 621 | 0.040 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 2215 | 0.040 |
Why?
|
| Cell Cycle | 3 | 2013 | 2153 | 0.040 |
Why?
|
| Aurora Kinases | 3 | 2004 | 193 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2004 | 1108 | 0.040 |
Why?
|
| Protein Array Analysis | 2 | 2013 | 505 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 783 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2012 | 1084 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2004 | 908 | 0.040 |
Why?
|
| Plasma Substitutes | 1 | 1997 | 12 | 0.040 |
Why?
|
| Tissue Distribution | 3 | 2005 | 948 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 1990 | 2316 | 0.040 |
Why?
|
| Response Elements | 2 | 2010 | 200 | 0.040 |
Why?
|
| Homozygote | 2 | 2013 | 759 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2012 | 431 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2011 | 691 | 0.040 |
Why?
|
| United States | 5 | 2014 | 16011 | 0.040 |
Why?
|
| COS Cells | 2 | 2010 | 422 | 0.040 |
Why?
|
| Chromothripsis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Imidazoles | 1 | 2003 | 1059 | 0.040 |
Why?
|
| Probability | 3 | 2004 | 876 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2012 | 210 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2004 | 1328 | 0.040 |
Why?
|
| Computational Biology | 2 | 2019 | 1263 | 0.040 |
Why?
|
| Cathepsin D | 2 | 2010 | 34 | 0.040 |
Why?
|
| Molecular Probes | 1 | 2017 | 71 | 0.040 |
Why?
|
| G2 Phase | 2 | 2001 | 218 | 0.040 |
Why?
|
| Medical Records | 2 | 2013 | 445 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 1323 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2017 | 663 | 0.030 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2016 | 40 | 0.030 |
Why?
|
| Karyotyping | 2 | 2003 | 1064 | 0.030 |
Why?
|
| Immunologic Surveillance | 1 | 2016 | 61 | 0.030 |
Why?
|
| Receptors, Steroid | 2 | 2009 | 356 | 0.030 |
Why?
|
| Aerobiosis | 1 | 2016 | 31 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2014 | 729 | 0.030 |
Why?
|
| Luciferases | 2 | 2010 | 462 | 0.030 |
Why?
|
| Interphase | 1 | 1996 | 156 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 1745 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 232 | 0.030 |
Why?
|
| Leukemia Inhibitory Factor | 3 | 2004 | 48 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 106 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 443 | 0.030 |
Why?
|
| Pyruvate Kinase | 1 | 2016 | 33 | 0.030 |
Why?
|
| Curcumin | 1 | 2016 | 119 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 395 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2008 | 1606 | 0.030 |
Why?
|
| Remission Induction | 2 | 2017 | 3646 | 0.030 |
Why?
|
| Myoepithelioma | 1 | 1995 | 32 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1996 | 254 | 0.030 |
Why?
|
| Zinc Finger Protein Gli2 | 1 | 2015 | 30 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2015 | 170 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 896 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2012 | 1348 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Lymphatic Irradiation | 2 | 2005 | 139 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 445 | 0.030 |
Why?
|
| Genitalia | 1 | 2014 | 47 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2015 | 82 | 0.030 |
Why?
|
| Serine | 2 | 2008 | 396 | 0.030 |
Why?
|
| Algorithms | 1 | 2006 | 3907 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 4190 | 0.030 |
Why?
|
| S Phase | 2 | 1993 | 290 | 0.030 |
Why?
|
| Recurrence | 4 | 2007 | 4884 | 0.030 |
Why?
|
| Cholecystitis | 1 | 1994 | 60 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2015 | 171 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2002 | 2089 | 0.030 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2005 | 113 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 315 | 0.030 |
Why?
|
| Adolescent | 5 | 2017 | 32554 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 5106 | 0.030 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2005 | 75 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2004 | 132 | 0.030 |
Why?
|
| Ligands | 2 | 2009 | 1061 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 466 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 1187 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 349 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 786 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2015 | 242 | 0.030 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2013 | 15 | 0.030 |
Why?
|
| Epidemiologic Factors | 1 | 2013 | 14 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 122 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2013 | 56 | 0.030 |
Why?
|
| Mammaplasty | 1 | 2000 | 715 | 0.030 |
Why?
|
| Fibroma | 1 | 1993 | 87 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 2 | 2006 | 584 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 17 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 4003 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 556 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 7786 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2013 | 101 | 0.030 |
Why?
|
| Peptides | 2 | 2013 | 1529 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2013 | 109 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 2012 | 54 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2013 | 124 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2011 | 1468 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2009 | 2617 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2013 | 130 | 0.030 |
Why?
|
| Early Detection of Cancer | 2 | 2011 | 1331 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1995 | 299 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 271 | 0.030 |
Why?
|
| Phenotype | 4 | 2005 | 6464 | 0.030 |
Why?
|
| Sialyltransferases | 1 | 2012 | 29 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2012 | 88 | 0.030 |
Why?
|
| Granular Cell Tumor | 1 | 1992 | 22 | 0.030 |
Why?
|
| Thyroid Neoplasms | 2 | 1991 | 1895 | 0.030 |
Why?
|
| Gallbladder Neoplasms | 1 | 1994 | 245 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 347 | 0.030 |
Why?
|
| Astrocytes | 1 | 2015 | 405 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 150 | 0.030 |
Why?
|
| Cisplatin | 1 | 2019 | 2496 | 0.030 |
Why?
|
| Open Reading Frames | 2 | 2005 | 273 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2013 | 313 | 0.020 |
Why?
|
| Carboplatin | 2 | 2011 | 879 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2013 | 249 | 0.020 |
Why?
|
| Texas | 3 | 2011 | 6414 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 600 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2011 | 84 | 0.020 |
Why?
|
| Methotrexate | 2 | 2010 | 1027 | 0.020 |
Why?
|
| Fertility | 1 | 2014 | 347 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2011 | 66 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2003 | 298 | 0.020 |
Why?
|
| GATA Transcription Factors | 1 | 2011 | 18 | 0.020 |
Why?
|
| Carcinogens | 2 | 2003 | 391 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1324 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 988 | 0.020 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2011 | 9 | 0.020 |
Why?
|
| Short Stature Homeobox Protein | 1 | 2011 | 12 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2002 | 484 | 0.020 |
Why?
|
| Mitosis | 2 | 2005 | 691 | 0.020 |
Why?
|
| Mitotic Index | 1 | 1991 | 166 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 679 | 0.020 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2011 | 57 | 0.020 |
Why?
|
| Brain | 2 | 2015 | 4251 | 0.020 |
Why?
|
| Mucins | 2 | 2008 | 289 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 1992 | 342 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1838 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2013 | 464 | 0.020 |
Why?
|
| Consensus | 1 | 2016 | 1113 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2004 | 349 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 715 | 0.020 |
Why?
|
| Blood Group Antigens | 1 | 1991 | 93 | 0.020 |
Why?
|
| Genomic Structural Variation | 1 | 2011 | 89 | 0.020 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 1984 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 1991 | 132 | 0.020 |
Why?
|
| Dysgerminoma | 1 | 1990 | 42 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 2561 | 0.020 |
Why?
|
| Neutropenia | 1 | 2015 | 1001 | 0.020 |
Why?
|
| Bronchial Neoplasms | 1 | 1990 | 83 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2010 | 400 | 0.020 |
Why?
|
| Piperazines | 1 | 2019 | 2154 | 0.020 |
Why?
|
| Body Height | 1 | 2011 | 232 | 0.020 |
Why?
|
| Intermediate Filaments | 1 | 1989 | 28 | 0.020 |
Why?
|
| Biliary Tract Neoplasms | 1 | 1992 | 179 | 0.020 |
Why?
|
| RNA | 2 | 2005 | 1067 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2009 | 60 | 0.020 |
Why?
|
| Genetic Markers | 2 | 2005 | 1015 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 279 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2002 | 1460 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1473 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 35 | 0.020 |
Why?
|
| DNA | 2 | 2002 | 3080 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 901 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2009 | 167 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2008 | 57 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 360 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 300 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 594 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 209 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2010 | 188 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 64 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2011 | 370 | 0.020 |
Why?
|
| Thymoma | 1 | 1992 | 253 | 0.020 |
Why?
|
| Fatigue | 1 | 2015 | 1280 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 1066 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 309 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 1091 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2009 | 203 | 0.020 |
Why?
|
| Morphogenesis | 1 | 2009 | 336 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2008 | 109 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 1435 | 0.020 |
Why?
|
| Metaplasia | 1 | 2009 | 386 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 674 | 0.020 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 528 | 0.020 |
Why?
|
| DNA Replication | 1 | 1991 | 772 | 0.020 |
Why?
|
| Stimulation, Chemical | 2 | 1998 | 112 | 0.020 |
Why?
|
| Receptors, CXCR | 1 | 2007 | 18 | 0.020 |
Why?
|
| Receptors, OSM-LIF | 2 | 1998 | 12 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 391 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2004 | 1184 | 0.020 |
Why?
|
| Crystallization | 2 | 1991 | 134 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 2 | 1998 | 21 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 102 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1989 | 410 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 704 | 0.020 |
Why?
|
| Thymus Neoplasms | 1 | 1992 | 420 | 0.020 |
Why?
|
| Cattle | 1 | 2008 | 846 | 0.020 |
Why?
|
| Lim Kinases | 1 | 2006 | 17 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 1038 | 0.020 |
Why?
|
| Transgenes | 1 | 2008 | 589 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 632 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 1346 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2005 | 58 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2005 | 51 | 0.020 |
Why?
|
| Heterozygote | 1 | 1989 | 1031 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 213 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 730 | 0.020 |
Why?
|
| Patient Selection | 2 | 2004 | 2041 | 0.020 |
Why?
|
| Smoking | 3 | 2002 | 2427 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2005 | 135 | 0.020 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2005 | 51 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 5783 | 0.020 |
Why?
|
| ras Proteins | 1 | 2009 | 803 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2004 | 68 | 0.020 |
Why?
|
| Nipples | 1 | 2005 | 124 | 0.020 |
Why?
|
| Research Design | 2 | 2004 | 1573 | 0.020 |
Why?
|
| Tubulin | 1 | 2005 | 203 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 671 | 0.020 |
Why?
|
| Neurofibromin 2 | 1 | 2004 | 41 | 0.020 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2005 | 143 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 261 | 0.020 |
Why?
|
| Clavicle | 1 | 2004 | 67 | 0.010 |
Why?
|
| Dyneins | 1 | 2004 | 33 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2005 | 282 | 0.010 |
Why?
|
| Stilbenes | 1 | 2005 | 94 | 0.010 |
Why?
|
| DNA Modification Methylases | 1 | 2005 | 176 | 0.010 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2004 | 52 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4389 | 0.010 |
Why?
|
| Integrin beta4 | 1 | 2004 | 24 | 0.010 |
Why?
|
| Ovary | 1 | 1988 | 701 | 0.010 |
Why?
|
| Digoxigenin | 1 | 2003 | 6 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 150 | 0.010 |
Why?
|
| Azo Compounds | 1 | 2003 | 15 | 0.010 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2004 | 169 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2005 | 269 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 169 | 0.010 |
Why?
|
| Artifacts | 1 | 2006 | 537 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2005 | 282 | 0.010 |
Why?
|
| Chromans | 1 | 2003 | 29 | 0.010 |
Why?
|
| Oxidative Stress | 2 | 2001 | 1160 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 1019 | 0.010 |
Why?
|
| Haplotypes | 1 | 2006 | 851 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 1666 | 0.010 |
Why?
|
| Alanine | 1 | 2004 | 251 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2004 | 171 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 6983 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2004 | 498 | 0.010 |
Why?
|
| Vacuum | 1 | 2003 | 42 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 1237 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 261 | 0.010 |
Why?
|
| Meat | 1 | 2003 | 93 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 228 | 0.010 |
Why?
|
| Trophoblasts | 1 | 2004 | 150 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 387 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2011 | 2118 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 208 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 236 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2004 | 624 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 362 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2003 | 116 | 0.010 |
Why?
|
| Apolipoproteins D | 1 | 2002 | 6 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2002 | 48 | 0.010 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2002 | 47 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 153 | 0.010 |
Why?
|
| Apocrine Glands | 1 | 2002 | 15 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 211 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2003 | 163 | 0.010 |
Why?
|
| Fenretinide | 1 | 2002 | 100 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 450 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 1079 | 0.010 |
Why?
|
| RNA Recognition Motif Proteins | 1 | 2002 | 19 | 0.010 |
Why?
|
| Models, Biological | 1 | 2011 | 3226 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1408 | 0.010 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 247 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2002 | 294 | 0.010 |
Why?
|
| Histiocytes | 1 | 2002 | 95 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 250 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 1432 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 280 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 952 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 149 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 540 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2007 | 2347 | 0.010 |
Why?
|
| DNA-Formamidopyrimidine Glycosylase | 1 | 2001 | 7 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 6647 | 0.010 |
Why?
|
| Deoxyribonuclease IV (Phage T4-Induced) | 1 | 2001 | 15 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 1573 | 0.010 |
Why?
|
| Environmental Pollutants | 1 | 2002 | 86 | 0.010 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2002 | 118 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 3431 | 0.010 |
Why?
|
| Deoxyguanosine | 1 | 2001 | 32 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2001 | 185 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 414 | 0.010 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2001 | 65 | 0.010 |
Why?
|
| RNA Helicases | 1 | 2002 | 103 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 1024 | 0.010 |
Why?
|
| Microscopy | 1 | 2002 | 193 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2002 | 374 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 888 | 0.010 |
Why?
|
| Chromosomes | 1 | 2002 | 323 | 0.010 |
Why?
|
| Research | 1 | 2003 | 427 | 0.010 |
Why?
|
| Prodrugs | 1 | 2002 | 226 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2002 | 306 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2002 | 260 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2002 | 267 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1472 | 0.010 |
Why?
|
| Keratin-7 | 1 | 2000 | 50 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 1150 | 0.010 |
Why?
|
| Protein Transport | 1 | 2002 | 739 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 612 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2002 | 442 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 2286 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2002 | 283 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 499 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 463 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 961 | 0.010 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2000 | 106 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 2000 | 85 | 0.010 |
Why?
|
| Flavonoids | 1 | 2000 | 201 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1524 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2002 | 449 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 7224 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 835 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2002 | 261 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 1092 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13876 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 188 | 0.010 |
Why?
|
| Guanine | 1 | 1999 | 157 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 1999 | 161 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 1135 | 0.010 |
Why?
|
| Diploidy | 1 | 1998 | 116 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 2306 | 0.010 |
Why?
|
| HIV-1 | 1 | 2002 | 641 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16930 | 0.010 |
Why?
|
| Electron Probe Microanalysis | 1 | 1997 | 8 | 0.010 |
Why?
|
| Sulfur | 1 | 1997 | 17 | 0.010 |
Why?
|
| Phylogeny | 1 | 2000 | 867 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1997 | 42 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1991 | 3236 | 0.010 |
Why?
|
| Autoradiography | 1 | 1996 | 158 | 0.010 |
Why?
|
| Leucovorin | 1 | 1997 | 344 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 7927 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1997 | 276 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 2049 | 0.010 |
Why?
|
| Mucin-1 | 1 | 1997 | 164 | 0.010 |
Why?
|
| Genome | 1 | 2000 | 683 | 0.010 |
Why?
|
| Monocytes | 1 | 2000 | 787 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2002 | 2852 | 0.010 |
Why?
|
| Child | 2 | 2014 | 30373 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1999 | 609 | 0.010 |
Why?
|
| Diet | 1 | 2003 | 1487 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1995 | 233 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1999 | 591 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1590 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 1996 | 278 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 5908 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1996 | 613 | 0.010 |
Why?
|
| Myoglobin | 1 | 1993 | 118 | 0.010 |
Why?
|
| Necrosis | 1 | 1995 | 604 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1999 | 1547 | 0.010 |
Why?
|
| Genes, Retinoblastoma | 1 | 1992 | 93 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 746 | 0.010 |
Why?
|
| Tracheal Neoplasms | 1 | 1992 | 44 | 0.010 |
Why?
|
| Isoantigens | 1 | 1991 | 67 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1991 | 65 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1990 | 58 | 0.010 |
Why?
|
| Carbazoles | 1 | 1990 | 92 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1990 | 237 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 2157 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 3492 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1992 | 424 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1990 | 615 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 1039 | 0.000 |
Why?
|
| Sex Factors | 1 | 1992 | 2191 | 0.000 |
Why?
|
| Vincristine | 1 | 1990 | 1572 | 0.000 |
Why?
|